JPMorgan analyst Anupam Rama lowered the firm’s price target on Sarepta (SRPT) to $28 from $30 and keeps an Overweight rating on the shares. The firm continues to see a “valuation disconnect” between the share price and potential of Sarepta’s overall commercial franchise. However, JPMorgan acknowledges that a long-term view is needed for a constructive outlook on the stock.
Claim 55% Off TipRanks
Trade SRPT with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta Therapeutics: Overcoming Setbacks with Promising Long-term Potential
- Sarepta Faces Legal Storm Over ELEVIDYS Trial Risks
- FDA flags possible safety signals in new report, says RBC Capital
- Sarepta, Circle, Dow, AMD, DoorDash: Trending by Analysts
- Sarepta put volume heavy and directionally bearish